In a study by Zhong et al., a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model demonstrated that FMT improved motor symptoms, reduced fecal SCFAs, and decreased alpha-synuclein expression in the substantia nigra pars compacta (SN), as measured by Western blot. The gene discussed is SNCA; the disease is Parkinson disease.